Premium
PML nuclear bodies: regulation, function and therapeutic perspectives
Author(s) -
Sahin Umut,
LallemandBreitenbach Valérie,
de Thé Hugues
Publication year - 2014
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.4426
Subject(s) - sumo protein , oxidative stress , function (biology) , interferon , biology , senescence , proteolysis , microbiology and biotechnology , ubiquitin , cancer research , immunology , genetics , biochemistry , gene , enzyme
PML nuclear bodies ( NBs ) were first described by electron microscopy and rediscovered through their treatment‐reversible disruption in a rare leukaemia. They recruit multiple partner proteins and now emerge as interferon‐ and oxidative stress‐responsive sumoylation factories. NBs mediate interferon‐induced viral restriction, enhance proteolysis, finely tune metabolism and enforce stress‐induced senescence. Apart from being markers of cellular stress, PML NBs could be harnessed pharmacologically in a number of conditions, including cancer, viral infection or neurodegenerative diseases. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.